ck data supports move into phase III. Merck highlighted its head and neck data, which was highly encouraging in our view. The study, which enrolled PD-L I+ recurrent and metastatic head and neck cancer patients, showed an ORR of 20% (11156) and 51% of patients exhibiting at least some tumor shrinkage